News

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clini ...
Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer’s disease ...
The Advanced Wound Care Summit is an ideal forum to showcase how FibroBiologics is pioneering the next generation of wound healing through our fibroblast-based technology," said Mr. O’Heeron. "Our ...
Milestone intends to use the net proceeds from the Offering, together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead ...
Capricor’s BLA for Deramiocel was granted Priority Review in March 2025 and was supported by data from the HOPE-2 trial, its open-label extension (OLE), and natural history comparisons from FDA-funded ...
Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the ...
In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation ...
Walmart Canada est la principale entreprise partenaire de la Croix-Rouge canadienne. Sa clientèle, ses associées et associés et elle ont permis d’amasser plus de 77 millions de dollars au profit de la ...
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that ...
Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor and Oppenheimer & Co. are acting as joint book-running managers for the public offering.
The Epilepsy Foundation of America (EFA) is proud to announce the appointment of Daryl Drabinsky, distinguished communications and corporate affairs executive, to its National Board of Directors.